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A B S T R A C T
This is a protocol for a Cochrane Review (Prototype). The objectives are as follows:
1. To assess the effectiveness of integrated care pathways compared to routine care for people with COPD and one or more
common comorbidities (quantitative data, RCTs).
2. To assess the effectiveness of an adapted or targeted single COPD intervention (simple or complex) that is aimed at changing the
management of people with COPD and one or more common comorbidities (quantitative data, RCTs).
3. To identify emerging themes that describe the views and experiences of patients, carers and healthcare professionals when
receiving or providing care to manage multi morbidities (qualitative data).
4. To use a mixed methods approach to combine quantitative and qualitative data resulting from objectives 1, 2 and 3, provided
that we find relevant data. If we find that we are unable to combine quantitative data and qualitative textual themes, we will present
the data and themes separately.
5. To identify any gaps in the evidence as a recommendation for further research.
B A C K G R O U N D
Description of condition
It is estimated that the global population of people aged 60 and
over will triple to 2.1 billion by 2050, with an increase of 32%
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in more developed countries, and 10% to 19% in less developed
countries (United Nations 2013). As more people live longer, the
number of chronic physical conditions that they may have are
likely to increase (Garin 2016; Academy of Medical Sciences
Report 2018).
The term ’multi morbidity’ is commonly used for the co-existence
of two or more chronic conditions, neither (or none) of which are
considered to be an index condition (Academy of Medical Sciences
Report 2018). Multimorbidity is associated with increasingly poor
health outcomes (including reduced quality of life; impaired func-
tional status; weakened physical and mental health; increased risk
of re-admission to hospital; and mortality) (Barnett 2012; Holland
2016; NICE 2018).
Prevalence of multi morbidity on a global level may be difficult
to determine as access to health care and diagnosis of chronic
conditions vary from country to country (Academy of Medical
Sciences Report 2018). However, one cross-sectional study has
recently shown prevalence of multi morbidity increases from over
40% to 70% in those aged 60 to 69 years across several low-
, middle- and high-income countries (China, Finland, Ghana,
India, Mexico, Poland, Russia, South Africa and Spain) (Garin
2016). It is estimated that approximately one in four people in the
UK live with two or more long-term conditions, rising to two-
thirds in people aged 65 and over (Barnett 2012; NHS England
2018; Salisbury 2018). In the countries investigated by the Garin
2016 study, chronic obstructive pulmonary disease (COPD) was
found to be associated with angina and asthma.
COPD is the name for a group of lung diseases (including bron-
chitis and emphysema). COPD occurs in adults (aged 35 years
and over), and is characterised by chronic airflow obstruction that
interferes with normal breathing and is not fully reversible (World
Health Organisation 2018). Diagnosis of COPD is based on peo-
ple experiencing day-to-day symptoms such as coughing, breath-
lessness (dyspnoea), and wheezing and frequent chest infections.
People may also experience periodic exacerbations (flare-ups). The
risk factors for COPD include smoking and environmental expo-
sures leading to abnormalities of the airways and alveoli (World
Health Organisation 2018; GOLD 2019). Further tests to di-
agnose COPD include spirometry, in which “the volume of air
forcibly exhaled from the point of maximal inspiration (forced
vital capacity, FVC), and the volume of air exhaled during the
first second (forced expiratory volume in one second, FEV )” are
measured. A FEV /FVC ratio of less than 0.70 is an indicator
for airway obstruction (GOLD 2019).
As COPD is associated with a high prevalence of multi morbidities
(Smith 2014), it is common for people with COPD to have more
than one co-existing long-term health condition that can vary in
nature and severity (Cavailles 2013; Holland 2016). People with
more severe COPD (GOLD stage D) are likely to have a higher
number of co-morbidities (Raherison 2018), which puts them at a
higher risk of mortality compared to people with mild or moderate
COPD, or those without COPD and co-existing long-term health
conditions (Mannino 2008; Divo 2012; Hanlon 2018).
Common long-term conditions that co-exist with COPD are car-
diovascular disease, hypertension, diabetes, asthma, and lung can-
cer (Hillas 2015). People may also live with long-term condition
system complexes such as frailty and chronic pain (Holland 2016;
Andenæs 2018). In this review we will treat pain as an outcome,
rather than a condition. These long-term conditions may or may
not be related to COPD.
In this review, we will focus on people with COPD living with
one or more long-term physical conditions (also referred to as co-
morbidities of COPD) (Holland 2016; Smith 2016). We do not
plan to include people with conditions caused by COPD treat-
ments, such as pneumonia, or ongoing conditions such as learning
disability, sensory impairment such as sight or hearing loss, and
alcohol and substance misuse.
Description of interventions
Interventions (treatments) for people with COPD are either aimed
at helping them to manage the symptoms of COPD in day-to-
day life, or are treatment of exacerbations (flare-ups). For treating
the symptoms, there are drugs including inhaled therapies (such as
long-acting beta -agonists, long-acting muscarinic antagonists,
and inhaled corticosteroids), phosphodiesterases and antibiotics,
as well as physical interventions such as pulmonary rehabilitation,
physical therapy (e.g. exercise), ventilation (e.g. non-invasive ven-
tilation (NIV)). For treating exacerbations there are inhaled ther-
apies, antibiotics and ventilation.
In this review we plan to look at COPD interventions which
target the co-morbidity (e.g. pulmonary rehabilitation where the
exercise component is taken in the swimming pool to enable people
with physical conditions to take part (McNamara 2013)). We will
also include interventions to improve the overall management of
people with COPD and one or more chronic conditions.
We have created a framework from the GOLD 2019 guidelines
and the Cochrane Airways subtopic list, from which we intend to
create an evidence (gap) map and use it as a basis for the analysis
(Table 1).
How will the intervention work?
Long-term conditions other than COPD may interfere with the
delivery of the COPD intervention. An example of people with
multi morbidity engaging with an intervention differently from
those with COPD alone is seen in pulmonary rehabilitation, one of
the more effective treatments for people with COPD (McCarthy
2015). Researchers have shown that people with multimorbid
COPD are more likely than people with COPD only to either
decline to enrol for treatment or, once enrolled, to drop out of
the programme or not attend sessions regularly (Fischer 2009;
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Keating 2011; Hayton 2013). Patients are more likely to drop
out of pulmonary rehabilitation programmes as a result of symp-
toms of other co-morbidities (Blackstock 2018). Furthermore, re-
searchers have evaluated the impact of co-existing conditions on
outcomes of a pulmonary rehabilitation intervention for people
with COPD which showed that depending on the co-existing con-
dition, pulmonary rehabilitation outcomes can be positive or neg-
ative (Crisafulli 2008; Carreiro 2013; Walsh 2013; Holland 2016).
Targeted interventions can help people take part in pulmonary
rehabilitation programmes: a targeted water-based exercise com-
ponent of a pulmonary rehabilitation programme was shown to
be more effective than land-based exercise (McNamara 2013). We
therefore intend to summarise evidence from randomised con-
trolled trials (RCTs) which target a COPD intervention to take
account of another co-morbidity.
People with multi morbidities may be taking multiple drugs for
each individual condition; for example, prescribed drugs, over-
the-counter treatments, herbal remedies or dietary supplements.
This is called polypharmacy and 16.4% of people over the age of
65 years are estimated to be taking 10 or more treatments each
day (Guthrie 2012; Duerden 2013). This can lead to unfavourable
drug interactions and practical issues with remembering to take so
many medications in a day. We will include interventions which
help people adapt to taking multiple medications; we will not,
however, be looking at polypharmacy interventions which aim to
optimise a patient’s drugs and reduce harmful drug interactions.
People with multi morbidities may also have to see many differ-
ent healthcare professionals to help them with various different
elements of their different long-term conditions. We will include
trials which aim to streamline (or simplify) this care in some way
to make it easier or better for the patient. These might include, for
example, putting a patient under the care of one particular consul-
tant who works across several hospital departments, thereby pro-
viding a holistic package of care. It may include a hospital putting
together an integrated disease management programme - a map
of a patient’s journey for managing their condition in a particular
location. We will also consider simpler interventions such as run-
ning COPD and cardiovascular clinics on the same day to reduce
the number of attendances at hospital.
Anxiety and depression are common in people with COPD. Phar-
macological and psychological interventions aimed at treating the
anxiety and depression are explored in a suite of Cochrane Re-
views (Pollok 2018; Pollok 2019; Usmani 2011; Usmani 2017).
Because the interventions are treating the co-morbidity rather than
the COPD, we will not include them in this review. We will also
not include studies of people with COPD who have symptoms of
depression or anxiety as the sole co-morbidity.
We present a draft logic model to help us and readers to think
about the interplay between different interventions and different
co-morbidities (Figure 1). We intend to take this model to our
Cochrane Airways Patient Advisory Group and Programme Grant
Steering Group for their consideration, and also to review it in
light of the evidence found in the review.
Figure 1. Map to show the complexity of interventions that may be required by people with COPD
depending on the number and combination of co-existing conditions they may have and the impact on short
term and long term outcomes
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Why is it important to do this review?
Most clinical trials are designed to involve people with one condi-
tion, and exclude people with multi morbidities - which may be
well over half of people who live with COPD. Therefore system-
atic reviews, including Cochrane Reviews, have also traditionally
focused on these patients, rather than including a sample repre-
senting the true population. This means that most studies may not
be applicable to people with more than one chronic condition: for
example, trials may only enrol people with COPD and exclude
people with asthma or heart disease. This means that we cannot
be confident about applying the results of the trial to people with
COPD and asthma, or people with COPD and heart disease.
There is a substantial health burden for people living with COPD
and multi morbidities, with associated cost implications due to an
increased need of hospital utilisation compared to patients who
only have one condition (Chen 2017). People living with multi
morbidity may also have to manage several symptoms, adhere to
multiple drug regimens and various lifestyle recommendations, all
while attending appointments with different healthcare providers
(Smith 2016). Healthcare services experience higher demands as
patients with multi morbidities require more frequent complex
care (Barnett 2012; Rijken 2018), and these services can be frag-
mented (Smith 2016).
Policy makers are increasingly aware that overall care for people
with multi morbidities needs to be patient-centred (i.e. care that
takes a patient’s needs into account, either via individual prefer-
ence, or by involving the patient in making decisions about their
care) and integrated (i.e. organisations and staff working together
to provide seamless care through processes that are flexible and
continuous) (Rijken 2016).
In addition, guidance for managing multi morbidities is limited
because of the exclusion from clinical trials of people living with
multi morbidity. The systematic failure of clinical trials to in-
clude people living with multi morbidity leads to care strategies
that may not be suitable or helpful for the majority of people
with COPD (Wyatt 2014). For example, multiple prescriptions
(polypharmacy) can lead to potential interactions between condi-
tions and medication resulting in inadequate and complex choices
of treatment in terms of benefit and harm (Sinnot 2013; Muth
2018), or fragmented and poorly coordinated care packages can
lead to complications such as over-hospitalisation when managing
patients with multi morbidities (Sinnot 2013; Rijken 2016).
We have decided to undertake this review because the Cochrane
Airways Patient Advisory Group and Programme Grant Steering
Group considered this to be an important topic to be reviewed
for a programme of Cochrane Airways reviews funded by the Na-
tional Institute for Health Research. The patients and healthcare
professionals agreed that the systematic review should report in-
formation about the clinical effectiveness of interventions, and the
views and experiences of those involved in managing multi mor-
bidities and COPD, and identify gaps in the evidence. The review
will address issues that are important for people with COPD who
have co-existing conditions, as well as for healthcare providers and
policy-makers.
Our scoping search of quantitative and qualitative evidence in this
topic area showed there are potential studies of either quantitative,
qualitative or mixed methods that investigate clinical effectiveness
of interventions and patient, healthcare professional or career per-
spectives of interventions.
In comparison with a previous Cochrane Review (Smith 2016),
we have decided to take a mixed methods approach to evaluate
the evidence that exists for people living with COPD and at least
one other chronic condition in this review because of concerns
that interventions begun with the best intentions may not always
be helpful for patients. This means we will identify studies con-
ducted in a community or hospital setting to combine both quan-
titative data (numerical data from clinical trials), and qualitative
data (non-numerical data from, for example, semi-structured in-
terviews, focus group discussions and patient, career or health pro-
fessional observations). To illustrate: we are aware of a local ex-
ample where people with COPD and heart disease have been put
under a coordinated care regime, but the patients have said they
prefer separate appointments because they are shorter and they
like having a reason to get out of the house.
We have deliberately left the types of intervention very broad (com-
pared to Smith 2016), to reflect the reality of people living with
COPD and other long-term health conditions in trying to make
sense of a sparse literature, who nonetheless need to make deci-
sions about how to manage their own symptoms and daily life.
The interventions are aimed to address COPD rather than the full
extent of multi morbidity.
There is a risk that we will not be able to meta-analyse any of the
data in the review according to our analysis plan below, in which
case we will map what is available and use this review to call for a
reconsideration of what trials need to be funded and run.
O B J E C T I V E S
1. To assess the effectiveness of integrated care pathways
compared to routine care for people with COPD and one or
more common comorbidities (quantitative data, RCTs).
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2. To assess the effectiveness of an adapted or targeted single
COPD intervention (simple or complex) that is aimed at
changing the management of people with COPD and one or
more common comorbidities (quantitative data, RCTs).
3. To identify emerging themes that describe the views and
experiences of patients, carers and healthcare professionals when
receiving or providing care to manage multi morbidities
(qualitative data).
4. To use a mixed methods approach to combine quantitative
and qualitative data resulting from objectives 1, 2 and 3,
provided that we find relevant data. If we find that we are unable
to combine quantitative data and qualitative textual themes, we
will present the data and themes separately.
5. To identify any gaps in the evidence as a recommendation
for further research.
M E T H O D S
Types of studies
We will include the following study designs to address the objec-
tives of this review.
• Randomised controlled trials (RCTs) to assess effectiveness
of interventions (quantitative data).
• Studies based on, for example, in-depth interviews, semi-
structured interviews, focus group discussion, observations, and
surveys to identify views, opinions and experiences of people
with COPD and multi morbidity, their carers and health
professionals involved in provision of care (qualitative data).
• Mixed methods studies (RCTs that also include a
qualitative analysis as part of their investigations).
Types of participants
We will include adults with a primary diagnosis of COPD of
any severity (e.g. Global Initiative for Chronic Obstructive Lung
Disease (GOLD), or American Thoracic Society (ATS) criteria), as
defined by objective evidence of airflow limitation on spirometry
in the context of a significant (more than 10 pack-years) smoking
history and living with at least one other long-term condition
(e.g. asthma, coronary heart disease, diabetes, atrial fibrillation,
heart failure, hypertension, stroke/transient Ischaemic attack, lung
cancer or osteoporosis (Barnett 2012)).
We will include people with COPD who also have anxiety or
depression or both, but this should not be the only co-morbidity.
We will include carers and healthcare professionals when receiving
or providing care to manage multi morbidities.
Types of interventions
We will include the following interventions for quantitative stud-
ies.
• An intervention aimed at changing the management of
people with COPD and one (or more) co-existing long-term
condition(s), which could be simple (e.g. scheduling COPD and
heart clinics on the same day) or more complex (e.g. developing
an integrated care package for management of people with
COPD in a particular hospital and providing training to staff to
deliver it), compared to routine care (or usual care, control, or no
intervention). We envisage these interventions being broken into
subgroups as follows.
◦ Organisation-wide interventions (such as introducing
a new care pathway)
◦ Simple changes within the organisation (such as
scheduling relevant clinics on the same day)
◦ Interventions across a wider area (such as integration
between GP, hospital and pharmacy)
• Any single intervention for COPD delivered to people with
COPD adapted or targeting their comorbidity (or
comorbidities) (e.g. participants receiving a pulmonary
rehabilitation programme tailored to take account of their
comorbidities by delivering the exercise component in water
rather than out of water (McNamara 2013)) compared to any
other intervention. We envisage these interventions being broken
into subgroups as follows.
◦ Pulmonary rehabilitation
◦ Exercise or other physical therapy
◦ Ventilation
◦ Pharmacotherapy (e.g. change of inhaler)
We will include interventions delivered in primary (community)
or secondary (hospital) care.
We will exclude studies of interventions that target the comorbid-
ity (e.g. we will exclude an intervention aimed at CVD).
We will exclude studies of pharmacological or psychological in-
terventions that target anxiety or depression or both rather than
COPD (previous Cochrane Reviews have, for example, included
COPD patients with either anxiety (Usmani 2017), depression
(Pollok 2018; Pollok 2019), or both anxiety and depression
(Usmani 2011)).
We will exclude interventions that are designed to reduce the
number of prescribed medicines or interactions between them
(polypharmacy), but we will include interventions that aim to help
people to manage polypharmacy.
We will exclude interventions delivered to healthcare professionals.
We will include qualitative studies that explore the experiences of
people taking part in the above interventions.
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Types of outcome measures
We will include the following outcomes for quantitative analysis.
Primary outcomes
• Quality of life (e.g. St. George’s Respiratory Questionnaire
(SGRQ), COPD assessment test (CAT))
• Exacerbations (as defined by trialists, depending on the data
available, we will extract either number of participants
experiencing one or more exacerbation, or the exacerbation rate,
or both)
Secondary outcomes
• Functional status (6-minute walk distance (6MWD)/
incremental shuttle walk test (ISWD))
• All-cause hospital admissions (also as a proxy for use of
services, e.g. reduction of use)
• Respiratory hospital admissions
• Mortality (all causes)
• Pain (as reported in trials)
• Anxiety symptoms (measured by e.g. Hospital Anxiety and
Depression Scale (HADS))
• Depression symptoms (measured by e.g. HADS)
For qualitative synthesis, we will identify themes that arise from
the data; however, we expect to find the following themes.
• Experience of living and treating more than one condition.
• Experience of services’ or healthcare barriers or facilitators
to intervention participation
• Intervention delivery
• Impact on quality of life and mood
• Mode of delivery
We will include studies regardless of whether or not they report
our pre-defined outcomes.
We will include studies of short-term and long-term duration of
interventions.
Search methods for identification of studies
Electronic searches
We will search for studies in the following databases and trials
registries.
• Cochrane Airways Register of Trials through the CRS, from
inception to date;
• Cochrane Central Register of Controlled Trials
(CENTRAL, in the Cochrane Library) through the Cochrane
Register of Studies (CRS), from inception to date;
• MEDLINE Ovid SP 1946 to date;
• Embase Ovid 1974 to date;
• PsycINFO Ovid Sp 1974 to date;
• CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature) 1937 to date;
• Web of Science Core Collection 1970 to date;
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov;
• World Health Organization International Clinical Trials
Registry Platform ( ICTRP).
Searches for qualitative and quantitative studies will be run sep-
arately using appropriate study design filters. We will combine
search terms for the target population with the Cochrane Highly
Sensitive Search Strategy to identify reports of RCTs (Lefebvre
2009), and terms from the search strategies developed and tested
by DeJean 2016 to find reports of qualitative studies. We list the
proposed MEDLINE search strategies in Appendix 2; these were
developed by ES, with input from the other authors, and were
peer-reviewed by another Information Specialist using the PRESS
checklist (McGowan 2016).
The MEDLINE search strategies will be adapted appropriately
for use in the other databases. We will search all databases from
their inception to the present, and there will be no restriction on
language of publication. We will not limit the search strategy with
respect to population characteristics such as age, gender or race.
Searching other resources
We will check the reference lists of all primary studies and re-
view articles for additional references. We will use the Epis-
temonikos database to search for relevant systematic reviews (
www.epistemonikos.org). We will search relevant manufacturers’
websites for study information.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed and report the date this was done
within the review.
Data collection and analysis
Selection of studies
We anticipate retrieving a large number of search results, and
therefore we are planning to use Cochrane’s ’Screen4Me’ work-
flow to help assess the results of our search for RCTs. Screen4Me
comprises three components: known assessments - a service that
matches records in the search results to records that have already
been screened in Cochrane Crowd and have been labelled as ’RCT’
or as ’Not an RCT’; the RCT classifier - a machine-learning model
that distinguishes RCTs from non-RCTs (Marshall 2018); and if
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appropriate, Cochrane Crowd - Cochrane’s citizen science plat-
form where ’the crowd’ help to identify and describe health evi-
dence (Noel-Storr 2018).
Following this, two of three review authors (SJ, ES and ED) will
screen each title and abstract of the remaining search results in-
dependently and code them as ’retrieve’ (eligible or potentially el-
igible/unclear) or ’do not retrieve’. We will retrieve the full-text
study reports of all potentially eligible studies and two of three re-
view authors (SJ, ES and ED) will independently screen each full
text for inclusion, recording the reasons for exclusion of ineligible
studies.
We will resolve any disagreement through discussion or, if re-
quired, we will consult a third review author (SH). We will identify
and exclude duplicates and collate multiple reports of the same
study so that each study, rather than each report, is the unit of
interest in the review. We will record the selection process in suf-
ficient detail to complete a PRISMA flow diagram and ’Charac-
teristics of excluded studies’ table (Moher 2009).
Data extraction and management
Two authors (SJ, ED, ES) will screen citations in Rayyan (Mourad
2016). One review author (SJ) will pilot the data extraction form
on at least one quantitative, one qualitative and one mixed meth-
ods study before extracting data from the rest of the included stud-
ies. We will extract data into Microsoft Excel.
Quantitative studies
One review author (SJ) will extract the following study character-
istics from included studies.
• Methods: study design, total duration of study, details of
any ’run-in’ period, number of study centres and location, study
setting, withdrawals and date of study.
• Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
• Interventions: intervention, comparison, concomitant
medications and excluded medications.
• Outcomes: primary and secondary outcomes specified and
collected (e.g. confidence intervals, P values, measurement scales
used), and time points reported. Definitions used to diagnose an
exacerbation will be sought and recorded.
• Notes: funding for studies and notable conflicts of interest
of trial authors.
A second review author (ED) will spot-check 10% to 20% of
characteristics extracted from studies by the first author.
Two review authors (SJ and ED) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus or
by involving a third person/review author (SH). One review au-
thor (SJ) will transfer quantitative data into the Review Manager
5 (RevMan 5) file (Review Manager 2014). We will double-check
that data are entered correctly by comparing the data presented in
the systematic review with the study reports. A second review au-
thor (ED) will spot-check study characteristics for accuracy against
the study report.
Qualitative studies
In order to capture context, two review authors (SJ and ED) will
extract the following study characteristics from included studies.
• Study details: country, study type (e.g. focus group, semi-
structured interviews, structured interviews, surveys), dates,
source of funding, objectives
• Participants: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria
• Methods: sampling, setting (e.g. community or hospital),
data collection (e.g. how the authors conducted the study, length
of interviews, whether interviews were recorded, use of interview
guide, data collected until achievement of thematic saturation),
data analysis (e.g. method of analysis of transcripts, framework
used, coding, thematic map)
• Results: authors’ interpretations, quotes from participants
provided by authors.
Assessment of risk of bias
Quantitative studies
Two review authors (SJ, and ED) will assess risk of bias indepen-
dently for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (SH). We will assess the risk of bias according to
the following domains.
• Random sequence generation
• Allocation concealment
• Blinding of participants and personnel
• Blinding of outcome assessment
• Incomplete outcome data
• Selective outcome reporting
• Other bias
We will judge each potential source of bias as high, low or unclear
and provide a quote from the study report together with a justifi-
cation for our judgement in the ’Risk of bias’ table. We will sum-
marise the risk of bias judgements across different studies for each
of the domains listed. We will consider blinding separately for dif-
ferent key outcomes where necessary (e.g. for unblinded outcome
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assessment, risk of bias for all-cause mortality may be very different
than for a patient-reported quality of life scale). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table. When
considering treatment effects, we will take into account the risk of
bias for the studies that contribute to that outcome.
We will present a ’Risk of bias’ table for all studies.
Qualitative studies
Two review authors (SJ and ED) will assess risk of bias indepen-
dently for each study using the criteria outlined by the Cochrane
Quality and Intervention Methods Group (Hannes 2011). We
will resolve any disagreements by discussion or by involving an-
other author (SH). We will assess the risk of bias according to the
following criteria.
• Quality of reporting (explicitness in reporting of all study
aspects)
• Methodological rigour (validity and reliability of study
design and process)
• Conceptual depth and breadth (are reported aims, rationale
or theory reflected in the study design, process and findings?)
We will use the Critical Appraisal Skills programme (CASP) check-
list to assess risk of bias. We will present risk of bias of studies in
tabular format.
We will assess the risk of bias after the identification of relevant
data when making judgements about relative strength of messages
in the included research.
Mixed methods studies
We will use the Mixed Methods Appraisal Tool (MMAT) to assess
risk of bias (Pluye 2011; Hong 2018). Two review authors (SJ and
ED) will assess risk of bias independently for each study using the
criteria outlined by the MMAT. We will resolve any disagreements
by discussion or by involving another author (SH). We will assess
the risk of bias according to the following criteria.
• Is there an adequate rationale for using a mixed methods
design to address the research question?
• Are the different components of the study effectively
integrated to answer the research question?
• Are the outputs of the integration of qualitative and
quantitative components adequately addressed?
• Are divergences and inconsistencies between quantitative
and qualitative results adequately addressed?
• Do the different components of the study adhere to the
quality criteria of each tradition of the methods involved?
Measurement of treatment effect
Quantitative treatment effects
We will analyse dichotomous data as odds ratios (OR) and con-
tinuous data as the mean difference (MD) or standardised mean
difference (SMD). If data from rating scales are combined in a
meta-analysis, we will ensure they are entered with a consistent
direction of effect (e.g. lower scores always indicate improvement).
We will undertake meta-analyses only where this is meaningful:
that is, if the treatments, participants and the underlying clinical
question are similar enough for pooling to make sense. If there is
substantial statistical or clinical heterogeneity we will present data
on graphs, but will not pool them. We will describe skewed data
narratively (for example, as medians and interquartile ranges for
each group).
Where multiple trial arms are reported in a single study, we will
include only the relevant arms. If two comparisons (e.g. interven-
tion A versus intervention B) are combined in the same meta-anal-
ysis, we will either combine the active arms or halve the control
group to avoid double-counting. If adjusted analyses are available
(ANOVA or ANCOVA), we will use these as a preference in our
meta-analyses. If both change from baseline and endpoint scores
are available for continuous data, we will use change from baseline
unless there is low correlation between measurements in individ-
uals. If a study reports outcomes at multiple time points, we will
use endpoint data. We will use intention-to-treat (ITT) or ’full
analysis set’ analyses where they are reported (i.e. those where data
have been imputed for participants who were randomly assigned
but did not complete the study) instead of completer or per pro-
tocol analyses.
Unit of analysis issues
Quantitative analysis
For dichotomous outcomes, we will use participants, rather than
events, as the unit of analysis. If rate ratios are reported in a study,
we will analyse them on this basis. We will only meta-analyse data
from cluster-RCTs if the available data have been adjusted (or can
be adjusted), to account for the clustering.
Dealing with missing data
We will contact investigators or study sponsors in order to verify
key study characteristics and obtain missing numerical outcome
data where possible (e.g. when a study is identified as an abstract
only). Where this is not possible, and the missing data are thought
to introduce serious bias, we will take this into consideration in
the GRADE rating for affected outcomes.
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Assessment of certainty of evidence
Quantitative data
We will use the five GRADE considerations (risk of bias, consis-
tency of effect, imprecision, indirectness, and publication bias) to
assess the quality of the body of evidence as it relates to the studies
that contribute data for the prespecified outcomes. We will use
the methods and recommendations described in Section 8.5 and
Chapter 12 of the Cochrane Handbook for Systematic Reviews of
Interventions ( Higgins 2011), using GRADEpro GDT software
(GRADEpro GDT; Guyatt 2008). We will justify all decisions
to downgrade the quality of studies in the footnotes of the table,
and we will make comments to aid the reader’s understanding of
the review where necessary. We will present GRADE findings in
a ’Summary of findings’ table.
Qualitative data
We will use the GRADE Confidence in the Evidence from Re-
views of Qualitative Research (CERQual) approach to assess our
confidence in the evidence of effectiveness arising from studies
evaluating interventions (Lewin 2015). This assessment will allow
us to make judgements on the following four domains.
• Methodological limitations of included studies
• Relevance of contributing studies to the research question
• Coherence of study findings
• Adequacy of data supporting the study findings
We will use the methods and recommendations described in chap-
ter 20 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions ( Higgins 2011). We will summarise findings of the four
domains for each outcome in a CERQual Qualitative Evidence
Profile (Lewin 2015). We will rate the overall assessment of con-
fidence of evidence as high, moderate, low or very low. We will
present CERQual findings in a ’Summary of findings’ table. We
will justify all decisions to downgrade the quality of studies in
the footnotes of the table, and we will make comments to aid the
reader’s understanding of the review where necessary.
Assessment of heterogeneity
Quantitative data
We will use the I² statistic to measure heterogeneity among the
studies in each analysis where possible. We will conduct a meta-
analysis using a random-effects model as we anticipate that the
interventions are likely to be varied. As we are uncertain of the in-
tervention effects, we will explore possible causes of heterogeneity
if there are sufficient studies.
We will consider the following I² ranges in the analyses (Higgins
2011).
1. 0% to 40%: might not be important
2. 30% to 60%: may represent moderate heterogeneity
3. 50% to 90%: may represent substantial heterogeneity
4. 75% to 100%: considerable heterogeneity
If we find that there is substantial statistical heterogeneity, we will
check the data for accuracy. If unexplained substantial heterogene-
ity persists, we will consider whether it is more appropriate to
present the standardised effect of each study in a forest plot with-
out performing a meta-analysis.
Assessment of reporting bias
Quantitative data
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small-study and publi-
cation biases.
Data synthesis
Quantitative data
We will use RevMan 5 to perform quantitative data syntheses
(meta-analyses) (Review Manager 2014); and where data for pop-
ulation or interventions are similar, we will pool such data. If it is
not possible to pool data, we will present the data in forest plots
to show the range of effect sizes where possible or tabulate and
describe in the text. If we do find that there is heterogeneity within
the studies we identify, we will take measures to ensure that we
limit variation by calculating standardised effect sizes, grouping
studies according to interventions and outcomes, and use the ran-
dom-effects model in the analyses (Ioannidis 2008). For studies
in which it is not possible to perform statistical analysis, we will
consider presenting data graphically and narratively using recom-
mendations in the latest version of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (in press).
Qualitative data
Where studies are similar in design we will synthesise data us-
ing a thematic analysis (Thomas 2008). This method allows us
to identify important or recurrent themes that arise from studies
and summarise them under thematic headings. We will tabulate
information, allowing identification of prominent themes and of-
fering structured ways of dealing with the data in each theme. This
type of synthesis will help us to identify emerging themes that de-
scribe the experiences of patients, carers and healthcare profession-
als when receiving or providing care to manage multi morbidities.
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We will initially analyse career and healthcare professional data
separately to identify, for example, conflicting views or experi-
ences. If we find that the views and experiences are similar, we will
combine the two subgroups in subsequent syntheses.
We will identify themes that describe the views and experiences
of carers and healthcare professionals when receiving or providing
care to manage multi morbidities. We will initially analyse career
and healthcare professional data separately to identify, for example,
conflicting views or experiences. If we find that the views and
experiences are similar, we will combine the two subgroups in
subsequent analyses.
Combining quantitative and qualitative data
We will use the methods and recommendations described in chap-
ter 20 of the Cochrane Handbook for Systematic Reviews of Interven-
tions, and methods outlined by the Cochrane Qualitative and Im-
plementation Methods Group ( Higgins 2011 and Harden 2018,
respectively). There are two main approaches to integrating qual-
itative and quantitative data: sequential and convergent. The se-
quential approach involves synthesising qualitative and quantita-
tive analyses separately, followed by using common frameworks to
integrate the findings across syntheses. We will use the sequential
approach to integrate qualitative data to explain quantitative find-
ings. We will analyse quantitative data at the first stage, followed
by synthesis of qualitative data in the second stage.
Integrating the qualitative syntheses with the quantitative analyses
can be achieved by using a ’matrix’ to compare and contrast find-
ings across both types of evidence. The matrix will help to identify
gaps in the evidence. This approach can help us to understand why
heterogeneity that we may find in the quantitative analyses exists.
Other approaches include the development of a ’logic model’ by
providing a common framework within which both quantitative
and qualitative evidence can contribute (Harden 2018). We ac-
knowledge that the methods for integration are dependent on the
quantity of studies and extracted evidence available, and quality
of description within included studies (e.g. intervention content,
context, and study findings). For divergent data (qualitative data
that does not match the quantitative data), we will aim to resolve
divergence (deviation of the qualitative data from the quantitative
data, or vice versa (Erzberger 1997)) where possible by providing a
narrative explanation according to research and knowledge of the
topic area.
Combining both quantitative and qualitative data will provide
better understanding of why some interventions are successful and
why other interventions are not so successful. This approach will
help to add richness and depth to quantitative findings which is not
methodologically possible to do when interpreting quantitative
data alone. We can identify areas where quantitative research may
be lacking but appears to be important to patients, carers or health
professionals (as identified from qualitative research).
Subgroup and investigation of heterogeneity
We will investigate heterogeneity such as statistical heterogeneity
of quantitative data. We plan to perform subgroup analyses if we
find heterogeneity using the following pre-specified groups.
• Number of multi morbidities in addition to COPD ( ≤ 2
conditions versus ≥ 3 conditions)
• Duration of intervention (< 3 months versus ≥ 3 months)
We will use the following outcomes in the subgroup analyses.
• Quality of life
• Functional status
• Hospital admissions
• Exacerbations
We will use the formal test for subgroup interactions in Review
Manager 5 (Review Manager 2014)
Sensitivity analysis
We plan to carry out sensitivity analysis excluding studies in which
one or more risk of bias domains is judged to be high risk of bias.
Assessment of bias conducting the systematic
review
We will conduct the review according to this published protocol
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
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A D D I T I O N A L T A B L E S
Table 1. Framework and map of interventions identified from included studies
Interven-
tions (identified from GOLD
2019 guideline and Cochrane
Airways subtopic list.)
Study Evidence type (quantitative, qualitative or
mixed methods)
Co-morbidities
• Reducing risk factors
◦ Smoking cessation
• Vaccination
◦ Pneumococcal
◦ Influenza
• Pharmacotherapies
◦ Short-acting inhalers
(e.g. SABA)
◦ Long-acting inhalers
(e.g. LABA, LAMA, ICS)
◦ Phosphodiesterase-4
(PDE4) inhibitors (e.g.
Roflumilast)
◦ Mucolytic agents
◦ Combination
inhalers and triple therapy
◦ Methyl xanthines
◦ Oral corticosteroids
◦ Antibiotics
◦ Statins
◦ Alpha-1 antitrypsin
augmentation therapy
◦ Biomarker mediated
therapy
• Rehabilitation, education
and self-management
◦ Pulmonary
rehabilitation
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Table 1. Framework and map of interventions identified from included studies (Continued)
◦ Exercise therapy (e.
g. upper limb exercise, ongoing
physical exercise after
pulmonary rehabilitation)
◦ Complementary
therapies (e.g. active mind-
body therapy, Tai chi, singing)
◦ Education and self-
management
• Organisation of care
◦ Support services (e.
g. social care, specialist
respiratory nurse)
◦ Integrated care
◦ Telehealthcare
◦ Digital management
interventions
◦ Home care
◦ Integrated disease
management (e.g. disease
management programming)
◦ Interventions to
promote or increase adherence
to PR or other treatments
• Other treatments
◦ Oxygen therapy and
ventilatory support (e.g. NIV,
ambulatory oxygen)
◦ Nutritional support
◦ Lung volume
reduction surgery
◦ Lung
transplantation
◦ Supportive,
palliative, end of life and
hospice care
◦ Psychotherapy
◦ interventions for
sexual dysfunction
◦ Self-help groups
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A P P E N D I C E S
Appendix 1. Definitions of study designs used in this review
Randomised study design
Observational,non-randomised study designs
Appendix 2. MEDLINE (Ovid) search strategy
Search to identify reports of RCTs
1 Lung Diseases, Obstructive/
2 exp Pulmonary Disease, Chronic Obstructive/
3 emphysema$.tw.
4 (chronic$ adj3 bronchiti$).tw.
5 (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).tw.
6 (COPD or COAD or COBD or AECB or AECOPD).ti,ab.
7 or/1-6
8 exp COMORBIDITY/
9 (comorbid$ or co-morbid$).tw.
10 (multidisease$ or multi-disease$ or ((multiple or coexist$ or co-exist$) adj2 (illness$ or disease$ or condition$ or syndrom$ or
disorder$))).ti,ab.
11 (multimorbid$ or multi-morbid$).tw.
12 exp Chronic Disease/
13 (chronic$ adj2 (illness$ or disease$ or condition$ or disorder$)).tw.
14 other health condition$.tw.
15 other medical condition$.tw.
16 (associated adj2 (disease$ or disorder$ or condition$ or illness$ or syndrome$)).tw.
17 or/8-16
18 7 and 17
19 (controlled clinical trial or randomized controlled trial).pt.
20 (randomized or randomised).ab,ti.
21 placebo.ab,ti.
22 dt.fs.
23 randomly.ab,ti.
24 trial.ab,ti.
25 groups.ab,ti.
26 or/19-25
27 Animals/
28 Humans/
29 27 not (27 and 28)
30 26 not 29
31 18 and 30
Search to identify reports of qualitative studies
1 Lung Diseases, Obstructive/
2 exp Pulmonary Disease, Chronic Obstructive/
3 emphysema$.tw.
4 (chronic$ adj3 bronchiti$).tw.
5 (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).tw.
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6 (COPD or COAD or COBD or AECB or AECOPD).ti,ab.
7 or/1-6
8 exp COMORBIDITY/
9 (comorbid$ or co-morbid$).tw.
10 (multidisease$ or multi-disease$ or ((multiple or coexist$ or co-exist$) adj2 (illness$ or disease$ or condition$ or syndrom$ or
disorder$))).ti,ab.
11 (multimorbid$ or multi-morbid$).tw.
12 exp Chronic Disease/
13 (chronic$ adj2 (illness$ or disease$ or condition$ or disorder$)).tw.
14 other health condition$.tw.
15 other medical condition$.tw.
16 (associated adj2 (disease$ or disorder$ or condition$ or illness$ or syndrome$)).tw.
17 or/8-16
18 7 and 17
19 qualitative research/
20 Interview/
21 (theme$ or thematic).mp.
22 qualitative.af.
23 Nursing Methodology Research/
24 questionnaire$.mp.
25 ethnological research.mp.
26 ethnograph$.mp.
27 ethnonursing.af.
28 phenomenol$.af.
29 (grounded adj (theor$ or study or studies or research or analys?s)).af.
30 (emic or etic or hermeneutic$ or heuristic$ or semiotic$).af. or (data adj1 saturat$).tw. or participant observ$.tw.
31 (social construct$ or (postmodern$ or post-structural$) or (post structural$ or poststructural$) or post modern$ or post-modern$
or feminis$ or interpret$).mp.
32 (action research or cooperative inquir$ or co operative inquir$ or co-operative inquir$).mp.
33 (humanistic or existential or experiential or paradigm$).mp.
34 (field adj (study or studies or research)).tw.
35 human science.tw.
36 biographical method.tw.
37 theoretical sampl$.af.
38 ((purpos$ adj4 sampl$) or (focus adj group$)).af.
39 (account or accounts or unstructured or openended or open ended or text$ or narrative$).mp.
40 (life world or life-world or conversation analys?s or personal experience$ or theoretical saturation).mp.
41 ((lived or life) adj experience$).mp.
42 cluster sampl$.mp.
43 observational method$.af.
44 content analysis.af.
45 (constant adj (comparative or comparison)).af.
46 ((discourse$ or discurs$) adj3 analys?s).tw.
47 narrative analys?s.af.
48 or/19-47
49 18 and 48
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